For patients with metastatic castration-resistant prostate cancer, treatment with rucaparib is associated with significantly longer duration of imaging-based progression-free survival compared with a control medication, according ...
Feb 17, 2023
0
17
A new prostate cancer therapy in clinical trials could treat patients resistant to treatment through targeting the disease on a molecular level, based on new Cleveland Clinic research.
Jan 17, 2023
0
29
In a new study published in Molecular Cancer Research, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable ...
Sep 22, 2022
0
31
A novel high-throughput screening assay is designed to identify inhibitors of the androgen receptor, which plays a critical role in the progression of prostate cancer. The assay could be used to identify new drugs to treat ...
Apr 6, 2022
0
24
A trio of drugs could delay the progression of metastatic castration-resistant prostate cancer.
Nov 3, 2021
0
12
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500 was safe and well tolerated with promising clinical benefit. Principal investigator ...
Oct 8, 2021
0
29
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase ...
Sep 29, 2020
0
9
(HealthDay)—For men with nonmetastatic, castration-resistant prostate cancer, the risk for death is significantly lower for those receiving darolutamide versus placebo, according to a study published in the Sept. 10 issue ...
Sep 15, 2020
0
3
Researchers from Boston University School of Medicine (BUSM) have discovered that the protein BRD4 could be an important new target to prevent castration-resistant prostate cancer metastases.
Jul 21, 2020
0
163
(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...
May 29, 2020
0
5
